bioRxiv · 10.64898/2026.02.25.707913
An injectable soft implant for long-acting, reversible, ultra-stable release of therapeutics
Abstract
Providing long-term (>6 months) zero-order drug release from easily administered formulations is a key challenge in improving patient adherence and facilitating access. Herein, we report the design and development of an injectable, biodegradable, long-acting polymeric microparticle-embedded hydrogel platform for prolonged, zero-order release of therapeutics. This "soft implant" is injectable for ease of administration and can be retrieved via a small incision, allowing for discontinuation of therapy if desired. Central to the platform are surface-eroding poly(orthoester) (POE) microparticles, which were molecularly tailored to tune zero-order drug release across a wide range of timeframes. We demonstrate the clinical potential of the "soft implant" using levonorgestrel, a contraceptive agent requiring sustained dosing. In vitro, we observed zero-order release for 300 days, projected for >12 months, with behavior consistent with surface erosion further supported through Raman chemical mapping. In vivo studies confirmed zero-order release for six months, projected to 12 months, from a subcutaneous injection in rats. We envision that our platform could transform therapies that require long-term, regular drug dosing, significantly improving compliance and therapy outcomes.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Stevens, M. M., Kütahya, C., Panariello, L., Najer, A., Rizou, T., Shamsabadi, A., Brachi, G., Peeler, D. J., Zharova, L., Fernandez Debets, T. F. F., Peschke, P., Constantinou, A. P., Xie, R., Cheng, Y., Burdis, R., Suarez-Bonnet, A., Cihova, M., Yeow, J., Schaufelberger, F., Malanchi, I.. 2026-02-26. An injectable soft implant for long-acting, reversible, ultra-stable release of therapeutics. https://doi.org/10.64898/2026.02.25.707913
Cite the original work for its findings. Save a collection to share your selection of sources.